For:
ads
Emerging Company Profile
T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a ...

Politics, Policy & Law
Latest executive order in spree to control biopharma centers on American-made drug products

An “America first” drug sourcing order signed Thursday is the latest in a series of attempts by President Donald Trump to bend the biopharma industry to his will in an effort to ...

Gilead disputes need for march-in rights to remdesivir to increase access, lower price

COVID-19 has spurred the latest demand for the federal government to exercise a power, yet unused, to lower drug prices by terminating a manufacturer’s exclusive license.

Deals
Data Bytes: Biogen marks Denali’s biggest deal yet

Denali’s deal with Biogen, which includes an

Read the full 70 word article

Finance
‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

Next year Andera aims to join the ranks of European life science VCs raising record funds with the close of its largest fund to date at €450 million.

Andera ...

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

Trump admin plan would pressure U.S.-listed Chinese companies
A Trump administration working group plan has recommended that Chinese companies listed on a U.S. ...

Management Tracks
Greene, an architect of Alnylam, looks to the next chapter

Barry Greene, who has worked with CEO John Maraganore to build Alnylam for the past 17 years, will depart the RNAi company as president at the end of the quarter.

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) appointed Uzair Qadeer as its first chief diversity officer. Previously, he served the rare diseases company as VP, head ...

BioCentury ISSN 1097-7201